封面
市場調查報告書
商品編碼
1229671

肝動脈化學栓塞療法(TACE)的全球市場:至2030年的預測

Transarterial Chemoembolization Market Forecast 2030

出版日期: | 出版商: Market Research Future | 英文 125 Pages | 商品交期: 請詢問到貨日

價格

全球肝動脈化學栓塞療法(TACE)的市場規模,預計至2030年的調查期間中以4.90%的年複合成長率成長,達到156億1,000萬美元。肝細胞癌症相關資訊的擴充和早期發現,醫療費增加,促進市場成長。

本報告提供全球肝動脈化學栓塞療法(TACE)市場相關調查分析,市場動態,市場分析,競爭情形,企業簡介等系統性資訊。

目錄

第1章 報告開端

第2章 市場簡介

  • 定義
  • 調查範圍
    • 調查目的
    • 假設
    • 限制事項

第3章 調查手法

  • 概要
  • 1次調查
  • 2次調查
  • 市場規模的估計

第4章 市場動態

  • 概要
  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場要素分析

  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭的激烈程度
  • 價值鏈分析

第6章 全球肝動脈化學栓塞療法(TACE)市場:各手術類型

  • 概要
  • 傳統式TACE
  • DEB-TACE

第7章 全球肝動脈化學栓塞療法(TACE)市場:各適應症

  • 概要
  • 無法切除HCC
  • 早期HCC

第8章 全球肝動脈化學栓塞療法(TACE)市場:各產品類型

  • 概要
  • 化療劑
    • 阿黴素
    • 順鉑(cisplatin)
    • Mitomycin
    • 其他
  • 放射治療藥
    • 釔-90微球
    • 碘-131 LIPIODOL
    • 錸-188 LIPIODOL
    • 磷-32玻璃微球
    • 鈥-166幾丁聚醣錯合
    • 其他
  • 藥物熔析粒子
    • 聚乙烯醇微球
    • 聚合物微球
    • 其他

第9章 全球肝動脈化學栓塞療法(TACE)市場:各終端用戶

  • 概要
  • 醫院和診所
  • 癌症研究中心
  • 其他

第10章 全球肝動脈化學栓塞療法(TACE)市場:各地區

  • 概要
  • 南北美洲
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 中東及非洲
    • 中東
    • 非洲

第11章 企業形勢

  • 概要
  • 競爭分析

第12章 企業簡介

  • ADVAXIS INC.
  • BAXTER
  • BELLICUM PHARMACEUTICALS, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • COOK
  • HIKMA PHARMACEUTICALS PLC
  • ISOFOL MEDICAL AB
  • NIPPON KAYAKU CO., LTD.
  • NOVARTIS
  • PFIZER
  • SIRTEX SIR-SPHERES PTY LTD.
  • SPECTRUM PHARMACEUTICALS, INC.
  • 其他

第13章 附錄

  • 參考文件
  • 相關報告
Product Code: MRFR/HC/7092-HCR

Market Overview

As per the most recent examination report, the transarterial chemoembolization (TACE) market is projected to arrive at USD 15.61 Billion by 2030 at a 4.90% CAGR during the review period. Hepatocellular carcinoma is an essential growth of the liver that grows for the most part because of persistent liver issues and cirrhosis in most cases. The sickness influences north of 500,000 people globally and is the third biggest reason for malignant growth mortality in the globe.

The utilization of transarterial chemoembolization achieves therapy for liver disease. It works on the standard of removing the bloodstream to the growth. When a stock has been cut off, chemotherapy is managed straightforwardly into the growth. Treatment for individuals with transitional-stage hepatocellular carcinoma is controlled intravenously. The customary transarterial chemoembolization market is respected to be the standard gold treatment for HCC in the US. It is additionally conceivable to use microspheres as medication transporters during transarterial chemoembolization, which might limit the degree of chemotherapeutics in the patient's foundational dissemination.

Moreover, the report likewise contains the perfection of elements, division, central participants, regional examination, and other fundamental variables. What's more, a definite examination of the global Transarterial Chemoembolization (TACE) Market estimate for 2025 is likewise remembered for the report. HCC is the fifth most analyzed disease on the planet, and it is the second most prominent reason for malignant growth mortality in guys all around the globe. The high-grade cervical disease is more normal in Asia and Africa.

Segmentation Overview

The market is fragmented based on applications, system type, product type, end-users, and regions. The global Transarterial Chemoembolization (TACE) Market trends are supposed to observe good development during the estimated time frame.

In view of the Application, the market is sectioned into Chemotherapeutic Specialists, Radiotherapeutic Specialists, and Medication eluting Particles. In view of the drive types, the market is fragmented into medical clinics and Facilities and Malignant growth Exploration Focuses.

Regional Analysis

The transarterial chemoembolization (TACE) market is seeing huge development in America due to expanded information on HCC and early recognition. Accordingly, the American Relationship of Liver Illnesses recommends that people in peril for HCC go through hepatic imaging once a half year to screen their condition. The medical services frameworks of Europe are among the best on the planet. Thusly, transarterial chemoembolization (TACE) market is seeing an expansion popular inferable from increment medical care costs.

As the world's most crowded mainland and where hepatocellular carcinoma is turning out to be increasingly normal, Asia-Pacific is home to the quickest developing TACE global market. There have been numerous occurrences in Asian countries.

Major Players

Major Players in the transarterial Chemoembolization (TACE) Market are Baxter (US), Novartis (Switzerland), Bellicum Pharmaceuticals, Inc. (US), Hikma Pharmaceuticals PLC (UK), Cook (US), Isofol Medical AB (Sweden), Nippon Kayaku Co., Ltd. (Japan), Pfizer (US), Sirtex SIR-Spheres Pty Ltd. (Australia), Boston Scientific Corporation (US), Spectrum Pharmaceuticals, Inc. (US), Advaxis Inc. (US), and Jiangsu Hengrui Medicine Co., Ltd. (China).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

  • 2.1. DEFINITION
  • 2.2. SCOPE OF THE STUDY
    • 2.2.1. RESEARCH OBJECTIVE
    • 2.2.2. ASSUMPTIONS
    • 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

  • 3.1. OVERVIEW
  • 3.2. PRIMARY RESEARCH
  • 3.3. SECONDARY RESEARCH
  • 3.4. MARKET SIZE ESTIMATION

4. MARKET DYNAMICS

  • 4.1. OVERVIEW
  • 4.2. DRIVERS
  • 4.3. RESTRAINTS
  • 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

  • 5.1. PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1. BARGAINING POWER OF SUPPLIERS
    • 5.1.2. BARGAINING POWER OF BUYERS
    • 5.1.3. THREAT OF NEW ENTRANTS
    • 5.1.4. THREAT OF SUBSTITUTES
    • 5.1.5. INTENSITY OF RIVALRY
  • 5.2. VALUE CHAIN ANALYSIS

6. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE

  • 6.1. OVERVIEW
  • 6.2. CONVENTIONAL TACE

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 6.3. DEB-TACE

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

7. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION

  • 7.1. OVERVIEW
  • 7.2. UNRESECTABLE HCC

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 7.3. EARLY-STAGE HCC

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

8. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE

  • 8.1. OVERVIEW
  • 8.2. CHEMOTHERAPEUTIC AGENTS
    • 8.2.1. DOXORUBICIN

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.2.2. CISPLATIN

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.2.3. MITOMYCIN

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.2.4. OTHERS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 8.3. RADIOTHERAPEUTIC AGENTS
    • 8.3.1. YTTRIUM-90 MICROSPHERES

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.3.2. IODINE-131 LIPIODOL

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.3.3. RHENIUM-188 LIPIODOL

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.3.4. PHOSPHORUS-32 GLASS MICROSPHERES

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.3.5. HOLMIUM-166 CHITOSAN COMPLEX

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.3.6. OTHERS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 8.4. DRUG-ELUTING PARTICLES
    • 8.4.1. POLYVINYL ALCOHOL MICROSPHERES

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

    • 8.4.2. POLYMER MICROSPHERES

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 8.5. OTHERS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

9. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS & CLINICS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 9.3. CANCER RESEARCH CENTERS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

  • 9.4. OTHERS

MARKET ESTIMATES & FORECAST, BY REGION, 2022-2030

MARKET ESTIMATES & FORECAST, BY COUNTRY, 2022-2030

10. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION

  • 10.1. OVERVIEW
  • 10.2. AMERICAS
    • 10.2.1. NORTH AMERICA
      • 10.2.1.1. US
      • 10.2.1.2. CANADA
    • 10.2.2. LATIN AMERICA
  • 10.3. EUROPE
    • 10.3.1. WESTERN EUROPE
      • 10.3.1.1. GERMANY
      • 10.3.1.2. FRANCE
      • 10.3.1.3. ITALY
      • 10.3.1.4. SPAIN
      • 10.3.1.5. UK
      • 10.3.1.6. REST OF WESTERN EUROPE
    • 10.3.2. EASTERN EUROPE
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. AUSTRALIA
    • 10.4.5. SOUTH KOREA
    • 10.4.6. REST OF ASIA-PACIFIC
  • 10.5. MIDDLE EAST & AFRICA
    • 10.5.1. MIDDLE EAST
    • 10.5.2. AFRICA

11. COMPANY LANDSCAPE

    • 11.1.1. OVERVIEW
    • 11.1.2. COMPETITIVE ANALYSIS

12. COMPANY PROFILES

  • 12.1. ADVAXIS INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. PRODUCT TYPE OVERVIEW
    • 12.1.3. FINANCIAL OVERVIEW
    • 12.1.4. KEY DEVELOPMENTS
    • 12.1.5. SWOT ANALYSIS
    • 12.1.6. KEY STRATEGIES
  • 12.2. BAXTER
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. PRODUCT TYPE OVERVIEW
    • 12.2.3. FINANCIAL OVERVIEW
    • 12.2.4. KEY DEVELOPMENTS
    • 12.2.5. SWOT ANALYSIS
    • 12.2.6. KEY STRATEGIES
  • 12.3. BELLICUM PHARMACEUTICALS, INC.
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. PRODUCT TYPE OVERVIEW
    • 12.3.3. FINANCIAL OVERVIEW
    • 12.3.4. KEY DEVELOPMENTS
    • 12.3.5. SWOT ANALYSIS
    • 12.3.6. KEY STRATEGIES
  • 12.4. BOSTON SCIENTIFIC CORPORATION
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. PRODUCT TYPE OVERVIEW
    • 12.4.3. FINANCIAL OVERVIEW
    • 12.4.4. KEY DEVELOPMENTS
    • 12.4.5. SWOT ANALYSIS
    • 12.4.6. KEY STRATEGIES
  • 12.5. COOK
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. PRODUCT TYPE OVERVIEW
    • 12.5.3. FINANCIAL OVERVIEW
    • 12.5.4. KEY DEVELOPMENTS
    • 12.5.5. SWOT ANALYSIS
    • 12.5.6. KEY STRATEGIES
  • 12.6. HIKMA PHARMACEUTICALS PLC
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. PRODUCT TYPE OVERVIEW
    • 12.6.3. FINANCIAL OVERVIEW
    • 12.6.4. KEY DEVELOPMENTS
    • 12.6.5. SWOT ANALYSIS
    • 12.6.6. KEY STRATEGIES
  • 12.7. ISOFOL MEDICAL AB
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. PRODUCT TYPE OVERVIEW
    • 12.7.3. FINANCIAL OVERVIEW
    • 12.7.4. KEY DEVELOPMENTS
    • 12.7.5. SWOT ANALYSIS
    • 12.7.6. KEY STRATEGIES
  • 12.8. NIPPON KAYAKU CO., LTD.
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. PRODUCT TYPE OVERVIEW
    • 12.8.3. FINANCIAL OVERVIEW
    • 12.8.4. KEY DEVELOPMENTS
    • 12.8.5. SWOT ANALYSIS
    • 12.8.6. KEY STRATEGIES
  • 12.9. NOVARTIS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. PRODUCT TYPE OVERVIEW
    • 12.9.3. FINANCIAL OVERVIEW
    • 12.9.4. KEY DEVELOPMENTS
    • 12.9.5. SWOT ANALYSIS
    • 12.9.6. KEY STRATEGIES
  • 12.10. PFIZER
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. PRODUCT TYPE OVERVIEW
    • 12.10.3. FINANCIAL OVERVIEW
    • 12.10.4. KEY DEVELOPMENTS
    • 12.10.5. SWOT ANALYSIS
    • 12.10.6. KEY STRATEGIES
  • 12.11. SIRTEX SIR-SPHERES PTY LTD.
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. PRODUCT TYPE OVERVIEW
    • 12.11.3. FINANCIAL OVERVIEW
    • 12.11.4. KEY DEVELOPMENTS
    • 12.11.5. SWOT ANALYSIS
    • 12.11.6. KEY STRATEGIES
  • 12.12. SPECTRUM PHARMACEUTICALS, INC.
    • 12.12.1. COMPANY OVERVIEW
    • 12.12.2. PRODUCT TYPE OVERVIEW
    • 12.12.3. FINANCIAL OVERVIEW
    • 12.12.4. KEY DEVELOPMENTS
    • 12.12.5. SWOT ANALYSIS
    • 12.12.6. KEY STRATEGIES
  • 12.13. OTHERS

13. APPENDIX

  • 13.1. REFERENCES
  • 13.2. RELATED REPORTS

LIST OF TABLES

  • TABLE 1 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SYNOPSIS, 2022-2030
  • TABLE 2 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET ESTIMATES & FORECAST, 2022-2030 (USD MILLION)
  • TABLE 3 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 8 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 10 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 11 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 12 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 13 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 14 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 15 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 16 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 17 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 18 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 19 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 20 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 21 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 22 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 23 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 24 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 25 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 26 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 27 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 28 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 29 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 30 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 31 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 32 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 33 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 34 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 35 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 36 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 37 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 38 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 39 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2022-2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 42 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 43 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2022-2030 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
  • FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
  • FIGURE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PROCEDURE TYPE, 2022 (%)
  • FIGURE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY INDICATION, 2022 (%)
  • FIGURE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PRODUCT TYPE, 2022 (%)
  • FIGURE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY END USER, 2022 (%)
  • FIGURE 8 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2022 (%)
  • FIGURE 7 AMERICAS: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE BY REGION, 2022 (%)
  • FIGURE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 10 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2022 (%)
  • FIGURE 11 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 12 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 13 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 14 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
  • FIGURE 15 ADVAXIS INC.: KEY FINANCIALS
  • FIGURE 16 ADVAXIS INC. SEGMENTAL REVENUE
  • FIGURE 17 ADVAXIS INC.: REGIONAL REVENUE
  • FIGURE 18 BAXTER: KEY FINANCIALS
  • FIGURE 19 BAXTER: SEGMENTAL REVENUE
  • FIGURE 20 BAXTER: REGIONAL REVENUE
  • FIGURE 21 BELLICUM PHARMACEUTICALS, INC.: KEY FINANCIALS
  • FIGURE 22 BELLICUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
  • FIGURE 23 BELLICUM PHARMACEUTICALS, INC.: REGIONAL REVENUE
  • FIGURE 24 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS
  • FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE
  • FIGURE 26 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE
  • FIGURE 27 COOK: KEY FINANCIALS
  • FIGURE 28 COOK: SEGMENTAL REVENUE
  • FIGURE 29 COOK: REGIONAL REVENUE
  • FIGURE 30 HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS
  • FIGURE 31 HIKMA PHARMACEUTICALS PLC: SEGMENTAL REVENUE
  • FIGURE 32 HIKMA PHARMACEUTICALS PLC: REGIONAL REVENUE
  • FIGURE 33 ISOFOL MEDICAL AB: KEY FINANCIALS
  • FIGURE 34 ISOFOL MEDICAL AB: SEGMENTAL REVENUE
  • FIGURE 35 ISOFOL MEDICAL AB: REGIONAL REVENUE
  • FIGURE 36 NIPPON KAYAKU CO., LTD.: KEY FINANCIALS
  • FIGURE 37 NIPPON KAYAKU CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 38 NIPPON KAYAKU CO., LTD.: REGIONAL REVENUE
  • FIGURE 39 NOVARTIS: KEY FINANCIALS
  • FIGURE 40 NOVARTIS: SEGMENTAL REVENUE
  • FIGURE 41 NOVARTIS: REGIONAL REVENUE
  • FIGURE 42 PFIZER: KEY FINANCIALS
  • FIGURE 43 PFIZER: SEGMENTAL REVENUE
  • FIGURE 44 PFIZER: REGIONAL REVENUE
  • FIGURE 45 SIRTEX SIR-SPHERES PTY LTD.: KEY FINANCIALS
  • FIGURE 46 SIRTEX SIR-SPHERES PTY LTD.: SEGMENTAL REVENUE
  • FIGURE 47 SIRTEX SIR-SPHERES PTY LTD.: REGIONAL REVENUE
  • FIGURE 48 SPECTRUM PHARMACEUTICALS, INC.: KEY FINANCIALS
  • FIGURE 49 SPECTRUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
  • FIGURE 50 SPECTRUM PHARMACEUTICALS, INC.: REGIONAL REVENUE